---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-011938"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2023-04-05T23:59:59+00:00"
generated_at: "2026-06-17T05:48:35.162544+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Acasti appoints Prashant Kohli as CEO; FDA allows Phase 3 safety study for GTX-104 to proceed

## Summary
- Prashant Kohli appointed CEO effective April 4, 2023, succeeding Jan D'Alvise who mutually agreed to depart.
- FDA Type C meeting response: concurred with 505(b)(2) pathway for GTX-104; Phase 3 safety study can proceed pending final protocol approval.
- Phase 3 trial: 1:1 randomized vs oral nimodipine in aSAH patients at 25-30 US sites; primary endpoint is safety (hypotension adverse events).
- First patient enrollment expected in H2 2023; if primary endpoint met, NDA filing under 505(b)(2) expected to follow.

## SEC filing metadata
- accession: 0000950170-23-011938
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2023-04-05T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017023011938/0000950170-23-011938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017023011938/acst-20230404.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-011938
- JSON: https://secwatch.observer/filing/0000950170-23-011938.json
- Plain text: https://secwatch.observer/filing/0000950170-23-011938.txt

## Key facts
- Executive change
  Jan D'Alvise departed as Director at Grace Therapeutics, Inc..
  - Action: stepping down
  - Role: Director
  source text: Ms. D'Alvise will also be stepping down from the Company's board of directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023011938/0000950170-23-011938-index.htm
- Executive change
  Jan D'Alvise departed as Chief Executive Officer at Grace Therapeutics, Inc..
  - Action: mutually agreed to depart
  - Role: Chief Executive Officer
  source text: succeeding Jan D'Alvise, who has mutually agreed with the Company to depart.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023011938/0000950170-23-011938-index.htm
- Executive change
  Prashant Kohli was appointed as Chief Executive Officer at Grace Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On April 4, 2023, Acasti Pharma Inc. (the "Company") announced it has appointed Prashant Kohli as the Company's Chief Executive Officer, succeeding Jan D'Alvise, who has mutually agreed with the Company to depart.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023011938/0000950170-23-011938-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.